In vivo treatment with calcilytic of CaSR knock-in mice ameliorates renal phenotype reversing downregulation of the vasopressin-AQP2 pathway.
AQP2
CaSR
autosomal dominant hypocalcaemia
calcilytic
microRNA
vasopressin
vasopressin type 2 receptor
Journal
The Journal of physiology
ISSN: 1469-7793
Titre abrégé: J Physiol
Pays: England
ID NLM: 0266262
Informations de publication
Date de publication:
17 Feb 2024
17 Feb 2024
Historique:
received:
17
10
2023
accepted:
30
01
2024
medline:
17
2
2024
pubmed:
17
2
2024
entrez:
17
2
2024
Statut:
aheadofprint
Résumé
High concentrations of urinary calcium counteract vasopressin action via the activation of the Calcium-Sensing Receptor (CaSR) expressed in the luminal membrane of the collecting duct cells, which impairs the trafficking of aquaporin-2 (AQP2). In line with these findings, we provide evidence that, with respect to wild-type mice, CaSR knock-in (KI) mice mimicking autosomal dominant hypocalcaemia, display a significant decrease in the total content of AQP2 associated with significantly higher levels of AQP2 phosphorylation at Ser261, a phosphorylation site involved in AQP2 degradation. Interestingly, KI mice also had significantly higher levels of phosphorylated p38MAPK, a downstream effector of CaSR and known to phosphorylate AQP2 at Ser261. Moreover, ATF1 phosphorylated at Ser63, a transcription factor downstream of p38MAPK, was significantly higher in KI. In addition, KI mice had significantly higher levels of AQP2-targeting miRNA137 consistent with a post-transcriptional downregulation of AQP2. In vivo treatment of KI mice with the calcilytic JTT-305, a CaSR antagonist, increased AQP2 expression and reduced AQP2-targeting miRNA137 levels in KI mice. Together, these results provide direct evidence for a critical role of CaSR in impairing both short-term vasopressin response by increasing AQP2-pS261, as well as AQP2 abundance, via the p38MAPK-ATF1-miR137 pathway. KEY POINTS: Calcium-Sensing Receptor (CaSR) activating mutations are the main cause of autosomal dominant hypocalcaemia (ADH) characterized by inappropriate renal calcium excretion leading to hypocalcaemia and hypercalciuria. Current treatments of ADH patients with parathyroid hormone, although improving hypocalcaemia, do not improve hypercalciuria or nephrocalcinosis. In vivo treatment with calcilytic JTT-305/MK-5442 ameliorates most of the ADH phenotypes of the CaSR knock-in mice including hypercalciuria or nephrocalcinosis and reverses the downregulation of the vasopressin-sensitive aquaporin-2 (AQP2) expression, providing direct evidence for a critical role of CaSR in impairing vasopressin response. The beneficial effect of calcilytic in reducing the risk of renal calcification may occur in a parathyroid hormone-independent action through vasopressin-dependent inhibition of cAMP synthesis in the thick ascending limb and in the collecting duct. The amelioration of most of the abnormalities in calcium metabolism including hypercalciuria, renal calcification, and AQP2-mediated osmotic water reabsorption makes calcilytic a good candidate as a novel therapeutic agent for ADH.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Regione Puglia - ResearchForInnovation
ID : 4FC8E072
Organisme : PON R&I 2014-2020
ID : IM1893457-3
Informations de copyright
© 2024 The Authors. The Journal of Physiology © 2024 The Physiological Society.
Références
Alfadda, T. I., Saleh, A. M. A., Houillier, P., & Geibel, J. P. (2014). Calcium-sensing receptor 20 years later. American Journal of Physiology-Cell Physiology, 307(3), C221-C231.
Ba, J., Brown, D., & Friedman, P. A. (2003). Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule phosphate transport. American Journal of Physiology-Renal Physiology, 285(6), F1233-F1243.
Brown, E. M., & Macleod, R. J. (2001). Extracellular calcium sensing and extracellular calcium signaling. Physiological Reviews, 81(1), 239-297.
Bustamante, M., Hasler, U., Leroy, V. C. A. A. R., De Seigneux, S., Dimitrov, M., Mordasini, D., Rousselot, M., Martin, P.-Y., & Féraille, E. (2008). Calcium-sensing receptor attenuates AVP-induced aquaporin-2 expression via a calmodulin-dependent mechanism. Journal of the American Society of Nephrology: JASN, 19(1), 109-116.
Centrone, M., Ranieri, M., Di Mise, A. D. i., Berlingerio, S. P., Russo, A., Deen, P. M. T., Staub, O., Valenti, G., & Tamma, G. (2017). AQP2 abundance is regulated by the E3-ligase CHIP Via HSP70. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 44(2), 515-531.
Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., & Varshavsky, A. (1989). A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science (New York, NY), 243(4898), 1576-1583.
De Groot, T., Bindels, R. J. M., & Hoenderop, J. G. J. (2008). TRPV5: an ingeniously controlled calcium channel. Kidney International, 74(10), 1241-1246.
Dong, B., Endo, I., Ohnishi, Y., Kondo, T., Hasegawa, T., Amizuka, N., Kiyonari, H., Shioi, G.o, Abe, M., Fukumoto, S., & Matsumoto, T. (2015). Calcilytic ameliorates abnormalities of mutant calcium-sensing receptor (CaSR) knock-in mice mimicking autosomal dominant hypocalcemia (ADH). Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 30(11), 1980-1993.
Ferreira, M. C. D. E. J., Héliès-Toussaint, C., Imbert-Teboul, M., Bailly, C., Verbavatz, J.-M., Bellanger, A.-C., & Chabardès, D. (1998). Co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in the cortical thick ascending limb cell of the rat kidney. Inhibition of hormone-dependent cAMP accumulation by extracellular Ca2+. The Journal of Biological Chemistry, 273(24), 15192-15202.
Fenton, R. A., & Moeller, H. B. (2008). Recent discoveries in vasopressin-regulated aquaporin-2 trafficking. Progress in Brain Research, 170, 571-579.
Finley, D., Sadis, S., Monia, B. P., Boucher, P., Ecker, D. J., Crooke, S. T., & Chau, V. (1994). Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant. Molecular and Cellular Biology, 14, 5501-5509.
Flick, K., Ouni, I., Wohlschlegel, J. A., Capati, C., Mcdonald, W. H., Yates, J. R., & Kaiser, P. (2004). Proteolysis-independent regulation of the transcription factor Met4 by a single Lys 48-linked ubiquitin chain. Nature Cell Biology, 6(7), 634-641.
Gafni, R. I., Brahim, J. S., Andreopoulou, P., Bhattacharyya, N., Kelly, M. H., Brillante, B. A., Reynolds, J. C., Zhou, H., Dempster, D. W., & Collins, M. T. (2012). Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 27(8), 1811-1820.
Gong, Y., Himmerkus, N., Plain, A., Bleich, M., & Hou, J. (2015). Epigenetic regulation of microRNAs controlling CLDN14 expression as a mechanism for renal calcium handling. Journal of the American Society of Nephrology: JASN, 26(3), 663-676.
Hebert, S. C., Brown, E. M., & Harris, H. W. (1997). Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. The Journal of Experimental Biology, 200(2), 295-302.
Hicke, L., & Dunn, R. (2003). Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annual Review of Cell and Developmental Biology, 19(1), 141-172.
Hoffert, J. D., Fenton, R. A., Moeller, H. B., Simons, B., Tchapyjnikov, D., Mcdill, B. W., Yu, M.-J., Pisitkun, T., Chen, F., & Knepper, M. A. (2008). Vasopressin-stimulated increase in phosphorylation at Ser269 potentiates plasma membrane retention of aquaporin-2. The Journal of Biological Chemistry, 283(36), 24617-24627.
Hoffert, J. D., Nielsen, J., Yu, M.-J., Pisitkun, T., Schleicher, S. M., Nielsen, S., & Knepper, M. A. (2007). Dynamics of aquaporin-2 serine-261 phosphorylation in response to short-term vasopressin treatment in collecting duct. American Journal of Physiology-Renal Physiology, 292(2), F691-F700.
Hoffert, J. D., Pisitkun, T., Wang, G., Shen, R.-F., & Knepper, M. A. (2006). Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites. Proceedings of the National Academy of Sciences of the United States of America, 103(18), 7159-7164.
Hough, T. A., Bogani, D., Cheeseman, M. T., Favor, J., Nesbit, M. A., Thakker, R. V., & Lyon, M. F. (2004). Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. The Proceedings of the National Academy of Sciences USA, 101(37), 13566-13571.
Isobe, K., Jung, H. J., Yang, C. R., Claxton, J., Sandoval, P., Burg, M. B., Raghuram, V., & Knepper, M. A. (2017). Systems-level identification of PKA-dependent signaling in epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 114, E8875-E8884.
Kim, J.-E., Jung, H. J., Lee, Y.u-J., & Kwon, T.-H. (2015). Vasopressin-regulated miRNAs and AQP2-targeting miRNAs in kidney collecting duct cells. American Journal of Physiology-Renal Physiology, 308(7), F749-F764.
Kimura, S., Nakagawa, T., Matsuo, Y., Ishida, Y., Okamoto, Y., & Hayashi, M. (2011). JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats. European Journal of Pharmacology, 668(1-2), 331-336.
Kumar, S., Matheny, C. J., Hoffman, S. J., Marquis, R. W., Schultz, M., Liang, X., Vasko, J. A., Stroup, G. B., Vaden, V. R., Haley, H., Fox, J., Delmar, E. G., Nemeth, E. F., Lago, A. M., Callahan, J. F., Bhatnagar, P., Huffman, W. F., Gowen, M., Yi, B., Danoff, T. M., & Fitzpatrick, L. A. (2010). An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone, 46(2), 534-542.
Li, W., & Ye, Y. (2008). Polyubiquitin chains: Functions, structures, and mechanisms. Cellular and Molecular Life Sciences: CMLS, 65(15), 2397-2406.
Matsumura, Y., Uchida, S., Rai, T., Sasaki, S., & Marumo, F. (1997). Transcriptional regulation of aquaporin-2 water channel gene by cAMP. Journal of the American Society of Nephrology: JASN, 8(6), 861-867.
Moeller, H. B., Olesen, E. T. B., & Fenton, R. A. (2011). Regulation of the water channel aquaporin-2 by posttranslational modification. American Journal of Physiology-Renal Physiology, 300(5), F1062-F1073.
Nedvetsky, P. I., Tabor, V., Tamma, G., Beulshausen, S., Skroblin, P., Kirschner, A., Mutig, K., Boltzen, M., Petrucci, O., Vossenkämper, A., Wiesner, B., Bachmann, S., Rosenthal, W., & Klussmann, E. (2010). Reciprocal regulation of aquaporin-2 abundance and degradation by protein kinase A and p38-MAP kinase. Journal of the American Society of Nephrology: JASN, 21(10), 1645-1656.
Nedvetsky, P. I., Tamma, G., Beulshausen, S., Valenti, G., Rosenthal, W., & Klussmann, E. (2009). Regulation of aquaporin-2 trafficking. Handbook of Experimental Pharmacology, 190, 133-157.
Pearce, S.h, & Thakker, R.v (1997). The calcium-sensing receptor: Insights into extracellular calcium homeostasis in health and disease. The Journal of Endocrinology, 154(3), 371-378.
Petrel, C., Kessler, A., Dauban, P., Dodd, R. H., Rognan, D., & Ruat, M. (2004). Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. The Journal of Biological Chemistry, 279(18), 18990-18997.
Pollak, M. R., Brown, E. M., Chou, Y.-H. W.u, Hebert, S. C., Marx, S. J., Stelnmann, B., Levi, T., Seidman, C. E., & Seidman, J. G. (1993). Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell, 75(7), 1297-1303.
Pollak, M. R., Brown, E. M., Estep, H. L., Mclaine, P. N., Kifor, O., Park, J.i, Hebert, S. C., Seidman, C. E., & Seidman, J. G. (1994). Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nature Genetics, 8(3), 303-307.
Procino, G., Carmosino, M., Tamma, G., Gouraud, S., Laera, A., Riccardi, D., Svelto, M., & Valenti, G. (2004). Extracellular calcium antagonizes forskolin-induced aquaporin 2 trafficking in collecting duct cells. Kidney International, 66(6), 2245-2255.
Procino, G., Mastrofrancesco, L., Mira, A., Tamma, G., Carmosino, M., Emma, F., Svelto, M., & Valenti, G. (2008). Aquaporin 2 and apical calcium-sensing receptor: New players in polyuric disorders associated with hypercalciuria. Seminars in Nephrology, 28(3), 297-305.
Procino, G., Mastrofrancesco, L., Tamma, G., Lasorsa, D. R., Ranieri, M., Stringini, G., Emma, F., Svelto, M., & Valenti, G. (2012). Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study. PLoS One, 7(3), e33145.
Ranieri, M. (2019). Renal Ca(2+) and water handling in response to calcium sensing receptor signaling: physiopathological aspects and role of CaSR-regulated microRNAs. International Journal of Molecular Sciences, 20(21), 5341.
Ranieri, M., Tamma, G., Di Mise, A., Russo, A., Centrone, M., Svelto, M., Calamita, G., & Valenti, G. (2015). Negative feedback from CaSR signaling to aquaporin-2 sensitizes vasopressin to extracellular Ca2. Journal of Cell Science, 128(13), 2350-2360.
Ranieri, M., Tamma, G., Di Mise, A., Vezzoli, G., Soldati, L., Svelto, M., & Valenti, G. (2013). Excessive signal transduction of gain-of-function variants of the calcium-sensing receptor (CaSR) are associated with increased ER to cytosol calcium gradient. PLoS One, 8(11), e79113.
Ranieri, M., Zahedi, K., Tamma, G., Centrone, M., Di Mise, A., Soleimani, M., & Valenti, G. (2018). CaSR signaling down-regulates AQP2 expression via a novel microRNA pathway in pendrin and NaCl cotransporter knockout mice. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 32(4), 2148-2159.
Riccardi, D., & Valenti, G. (2016). Localization and function of the renal calcium-sensing receptor. Nature Reviews Nephrology, 12(7), 414-425.
Roszko, K. L., Hu, T. Y., Guthrie, L. C., Brillante, B. A., Smith, M., Collins, M. T., & Gafni, R. I. (2022). PTH 1-34 replacement therapy has minimal effect on quality of life in patients with hypoparathyroidism. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 37(1), 68-77.
Roszko, K. L., Stapleton Smith, L. M., Sridhar, A. V., Roberts, M. S., Hartley, I. R., Gafni, R. I., Collins, M. T., Fox, J. C., & Nemeth, E. F. (2022). Autosomal dominant hypocalcemia type 1: A systematic review. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 37(10), 1926-1935.
Sadowski, M., Suryadinata, R., Tan, A. R., Roesley, S. N. A., & Sarcevic, B. (2012). Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes. Iubmb Life, 64(2), 136-142.
Sands, J. M., Flores, F. X., Kato, A., Baum, M. A., Brown, E. M., Ward, D. T., Hebert, S. C., & Harris, H. W. (1998). Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats. The American Journal of Physiology, 274, F978-F985.
Sands, J. M., Naruse, M., Baum, M., Jo, I., Hebert, S. C., Brown, E. M., & Harris, H. W. (1997). Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. The Journal of Clinical Investigation, 99(6), 1399-1405.
Sikjaer, T., Rejnmark, L., Rolighed, L., Heickendorff, L., & Mosekilde, L. (2011). The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 26(10), 2358-2370.
Tamma, G., Di Mise, A., Ranieri, M., Svelto, M., Pisot, R., Bilancio, G., Cavallo, P., De Santo, N. G., Cirillo, M., & Valenti, G. (2014). A decrease in aquaporin 2 excretion is associated with bed rest induced high calciuria. Journal of translational medicine, 12(1), 133.
Tamma, G., Ranieri, M., Di Mise, A., Centrone, M., Svelto, M., & Valenti, G. (2014). Glutathionylation of the aquaporin-2 water channel: A novel post-translational modification modulated by the oxidative stress. The Journal of Biological Chemistry, 289(40), 27807-27813.
Tan, Y., Rouse, J., Zhang, A., Cariati, S., Cohen, P., & Comb, M. J. (1996). FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. The EMBO Journal, 15(17), 4629-4642.
Theman, T. A., Collins, M. T., Dempster, D. W., Zhou, H., Reynolds, J. C., Brahim, J. S., Roschger, P., Klaushofer, K., & Winer, K. K. (2009). PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 24(5), 964-973.
Thrower, J. S. (2000). Recognition of the polyubiquitin proteolytic signal. The EMBO Journal, 19(1), 94-102.
Toka, H. R., Pollak, M. R., & Houillier, P. (2015). Calcium sensing in the renal tubule. Physiology (Bethesda, Md), 30, 317-326.
Trepiccione, F., Pisitkun, T., Hoffert, J. D., Poulsen, S. B., Capasso, G., Nielsen, S., Knepper, M. A., Fenton, R. A., & Christensen, B. M. (2014). Early targets of lithium in rat kidney inner medullary collecting duct include p38 and ERK1/2. Kidney International, 86(4), 757-767.
Vezzoli, G., Terranegra, A., Rainone, F., Arcidiacono, T., Cozzolino, M., Aloia, A., Dogliotti, E., Cusi, D., & Soldati, L. (2011). Calcium-sensing receptor and calcium kidney stones. Journal of Translational Medicine, 9(1), 201.
Ward, D., & Riccardi, D. (2002). Renal physiology of the extracellular calcium-sensing receptor. Pflugers Archiv: European Journal of Physiology, 445(2), 169-176.
Zarubin, T., & Han, J. (2005). Activation and signaling of the p38 MAP kinase pathway. Cell Research, 15(1), 11-18.